SCHEMBL20239178

SCHEMBL20239178

NCc1cc(Oc2ccc(CS(N)(=O)=O)cc2)nc(N2CCOCC2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.55
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 4/20 0.52
CYP1A2 P05177 3/20 0.52
CYP2C9 P11712 3/20 0.52
CYP2C19 P33261 3/20 0.52
CYP2D6 P10635 1/20 0.52
ATM Q13315 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.47
HTT P42858 2/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 2/20 0.45
NPSR1 Q6W5P4 1/20 0.40
CA12 O43570 3/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA9 Q16790 3/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239273 0.88 DGAT2 (0.70) DGAT2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL20239202 0.84 LMNA (0.54) DGAT2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL20239363 0.83 DGAT2 (0.81) DGAT2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL20239207 0.77 SMN1; SMN2 (0.48) DGAT2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL16738665 0.76 DGAT2 (0.44) DGAT2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL20252446 0.73 DGAT2 (0.42) DGAT2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL20239260 0.73 DGAT2 (0.46) DGAT2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL20239281 0.72 DGAT2 (0.61) DGAT2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL20239199 0.71 DGAT2 (1.00) DGAT2CA12CA1CA2CA9
SCHEMBL20239298 0.71 DGAT2 (0.81) DGAT2MEN1KMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885MEN1 4508/4885KMT2A 1748/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885MEN1 4407/4885KMT2A 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.